KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Gross Margin (2019 - 2025)

Alnylam Pharmaceuticals' Gross Margin history spans 7 years, with the latest figure at 75.6% for Q4 2025.

  • For Q4 2025, Gross Margin fell 710.0% year-over-year to 75.6%; the TTM value through Dec 2025 reached 78.5%, down 787.0%, while the annual FY2025 figure was 81.77%, 460.0% down from the prior year.
  • Gross Margin reached 75.6% in Q4 2025 per ALNY's latest filing, down from 84.21% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 89.8% in Q2 2024 to a low of 133.94% in Q1 2025.
  • Average Gross Margin over 5 years is 74.03%, with a median of 85.61% recorded in 2021.
  • Peak YoY movement for Gross Margin: surged 1344bps in 2024, then plummeted -22290bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 86.99% in 2021, then dropped by -1bps to 86.22% in 2022, then dropped by -3bps to 83.63% in 2023, then dropped by -1bps to 82.69% in 2024, then dropped by -9bps to 75.6% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Gross Margin are 75.6% (Q4 2025), 84.21% (Q3 2025), and 81.64% (Q2 2025).